- Previous Close
5.98 - Open
6.26 - Bid 5.52 x 100
- Ask 5.83 x 100
- Day's Range
5.52 - 6.26 - 52 Week Range
1.62 - 29.28 - Volume
102,715 - Avg. Volume
3,730,391 - Market Cap (intraday)
10.779M - Beta (5Y Monthly) 2.09
- PE Ratio (TTM)
-- - EPS (TTM)
-6.32 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.33
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
www.dwtx.comRecent News: DWTX
View MorePerformance Overview: DWTX
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DWTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DWTX
View MoreValuation Measures
Market Cap
10.78M
Enterprise Value
8.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
11.35
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.52%
Return on Equity (ttm)
-36.28%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.86M
Diluted EPS (ttm)
-6.32
Balance Sheet and Cash Flow
Total Cash (mrq)
14.85M
Total Debt/Equity (mrq)
24.25%
Levered Free Cash Flow (ttm)
--